Diabetes Research and Clinical Practice
Volume 77, Issue 1 , Pages 107-112, July 2007

Differences in coronary heart disease prevalence and risk factors in African and White patients with type 2 diabetes

  • W. John Kalk

      Affiliations

    • Corresponding Author InformationCorresponding author at: Diabetes Centre, Derbyshire Royal Infirmary, London Road, Derby DE1 2QY, United Kingdom. Tel.: +44 1332 347141x2710; fax: +44 1332 254836.
  • ,
  • Barry I. Joffe

Department of Medicine, University of the Witwatersrand, Johannesburg, South Africa

Received 19 April 2006; accepted 13 October 2006. published online 06 December 2006.

Abstract 

Coronary heart disease (CHD) is rare in sub-Saharan Africans; there are few data in African diabetic populations. We therefore evaluated the prevalence of CHD and conventional risk factors in 744 consecutive African (A, n=448) and White European (W, n=296) subjects with type 2 diabetes. CHD was present in 4% of A and in 23% of W (p<0.001). Compared with W, the A groups had lower total cholesterol (TC) and triglyceride (TG) levels: men: TC—W, 5.76 (S.D., 1.36) and A, 4.98 (1.29)mmol/l; TG—W, 2.10 (IQR,1.40–3.00) and A, 1.60 (1.10–2.55)mmol/l; women: TC—W, 5.85 (1.31) and A, 5.20 (1.24); TG—2.00 (1.40–2.90) and A, 1.40 (1.00–2.03)mmol/l (p0.0022 for each comparison). The A had significantly lower TG:HDL-C ratios (an index of insulin resistance) (p=0.004) and were less likely to have (estimated) small dense LDL-C particles (p0.038). In subjects with established CHD traditional risk factors were similar in A and W. Regression analysis revealed that CHD associated in A with serum creatinine (p=0.0015) and TC (p=0.038) and with TG in W (p=0.0072). We conclude that the rarity of CHD in diabetic Africans can be explained by contributions of low TC levels and probably lesser insulin resistance and its consequences; renal disease may be an important additional risk factor.

Keywords: African diabetes, Coronary heart disease, CHD risk factors

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Presented in part at the XV International Symposium on Drugs Affecting Lipid Metabolism, Venice, 2004.

PII: S0168-8227(06)00485-2

doi:10.1016/j.diabres.2006.10.014

Diabetes Research and Clinical Practice
Volume 77, Issue 1 , Pages 107-112, July 2007